Implications of transcriptional factor, OCT-4, in human bladder malignancy and tumor recurrence

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 829-834

  Huang, Peng ^a   Chen, Jie ^a   Wang, Lei ^a,b   Na, Yanqun ^b   Kaku, Haruki ^a   Ueki, Hideo ^a   Sasaki, Katsumi ^a   Yamaguchi, Ken ^a   Zhang, Kai ^c   Saika, Takashi ^a   Nasu, Yasutomo ^a   Watanabe, Masami ^a   Kumon, Hiromi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^c PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Bladder cancer; High grade; Immunostaining; OCT 4; Recurrence

Indexed keywords

OCTAMER TRANSCRIPTION FACTOR 4; POU5F1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER TISSUE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSURETHRAL RESECTION; BLADDER TUMOR; CANCER STAGING; ENZYME IMMUNOASSAY; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OCTAMER TRANSCRIPTION FACTOR-3; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84865278037     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9962-4     Document Type: Article

References (17)

1. Khaled HM, Bahnassi AA, Zekri AR, Kassem HA, Mokhtar N. Correlation between p53 mutations and HPV in bilharzial bladder cancer. Urol Oncol. 2003;21:334-41.
2. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006;355:1253-61.
3. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105-11.
4. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983-8.
5. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106-10.
6. Burdon T, Smith A, Savatier P. Signalling, cell cycle and pluripotency in embryonic stem cells. Trends Cell Biol. 2002;12: 432-8.
7. Niwa H, Miyazaki J, Smith AG. Quantitative expression of Oct- 3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Gene. 2000;24:372-6.
8. Gidekel S, Pizov G, Bergman Y, Pikarsky E. Oct-3/4 is a dosedependent oncogenic fate determinant. Cancer Cell. 2003;4: 361-70.
9. Looijenga LH, Stoop H, de Leeuw HP, de Gouveia Brazao CA, Gillis AJ, van Roozendaal KE, van Zoelen EJ, Weber RF, Wolffenbuttel KP, van Dekken H, Honecker F, Bokemeyer C, Perlman EJ, Schneider DT, Kononen J, Sauter G, Oosterhuis JW. POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res. 2003;63:2244-50.
10. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 2008;40:499-507.
11. Watanabe M, Kashiwakura Y, Huang P, Ochiai K, Futami J, Li SA, Takaoka M, Nasu Y, Sakaguchi M, Huh NH, Kumon H. Immunological aspects of REIC/Dkk-3 in monocyte differentiation and tumor regression. Int J Oncol. 2009;34:657-63.
12. Zhang K, Watanabe M, Kashiwakura Y, Li SA, Edamura K, Huang P, Yamaguchi K, Nasu Y, Kobayashi Y, Sakaguchi M, Ochiai K, Yamada H, Takei K, Ueki H, Huh NH, Li M, Kaku H, Na Y, Kumon H. Expression pattern of REIC/Dkk-3 in various cell types and the implications of the soluble form in prostatic acinar development. Int J Oncol. 2010;37:1495-501.
13. Huang HY, Shariat SF, Sun TT, Lepor H, Shapiro E, Hsieh JT, Ashfaq R, Lotan Y, Wu XR. Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome. Hum Pathol. 2007;38:1703-13.
14. Denzinger S, Mohren K, Knuechel R, Wild PJ, Burger M, Wieland WF, Hartmann A, Stoehr R. Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses. Hum Pathol. 2006;37:143-51.
15. Sidransky D, Frost P, Von Eschenbach A, Oyasu R, Preisinger AC, Vogelstein B. Clonal origin bladder cancer. N Engl J Med. 1992;326:737-40.
16. Junker K, Wolf M, Schubert J. Molecular clonal analysis of recurrent bladder cancer. Oncol Rep. 2005;14:319-23.
17. Cheng L, Sung MT, Cossu-Rocca P, Jones TD, MacLennan GT, De Jong J, Lopez-Beltran A, Montironi R, Looijenga LH. OCT4: biological functions and clinical applications as a marker of germ cell neoplasia. J Pathol. 2007;211:1-9.